All Drug Delivery articles – Page 11
-
NewsSynthetic proteins key to modular nanoparticle design
Researchers have been able to customise nanoparticles to target biological entities, like tumours and viruses.
-
News
Explosive cell death: inflammation-causing gene
WEHI researchers have found that a genetic change of MLKL increases risk of uncontrolled inflammatory response
-
WebinarComplete aggregate and particle characterisation of protein, gene and cell therapies
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
-
ArticleAntibody-drug conjugates payloads: then, now and next
Dr Nicolas Camper at CDMO Abzena and colleagues offer insight into the landscape of antibody-drug conjugates and how the therapy is evolving.
-
ArticleAddressing increasingly resistant drugs by infectious agents
Infectious agents' drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.
-
ArticleTherapeutic frontiers: the potential of RRx-001 and AdAPT-001
Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.
-
NewsBreakthrough treatment defeats deadly fungus
Researchers at the RIKEN Center for Sustainable Research Science (CSRS) and the University of Toronto have discovered a method to combat fungal infections by targeting their fatty acid production.
-
NewsCracking the code of influenza evolution
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
-
ArticlePrecision medicine: exploring the impact of DNA Testing
The potential of precision medicine requires a small shift in perspective, Patrick Short, CEO and co-founder of Sano Genetics, explains in this Q&A.
-
ReportBeyond the lab: cell & gene therapy
The launch of our new series, "Beyond the Lab," promises to deliver high-level insights commissioned exclusively by Drug Target Review magazine. Our inaugural report is an exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery.
-
ArticleThe future of central nervous system research
Central nervous system (CNS) research is making breakthroughs with innovative therapies and next-generation technologies. Researchers are now able to use human tissue to identify relevant novel drug targets and biomarkers for a broad range of CNS diseases including schizophrenia, Alzheimer’s disease and Parkinson’s disease. As our understanding of the brain ...
-
ArticleRare autoantibody diseases: an innovative targeted pathway
Dr Katie Abouzahr outlines how precision targeting utilising the neonatal fragment crystallisable receptor pathway may provide accessible new treatments for autoantibody diseases.
-
ArticleEpigenetic editing: the next generation of genetic medicine
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.
-
ArticleExploring alternatives to animal testing in drug discovery
The use of animal studies in drug development has become a growing ethical concern, particularly given the high failure rate of clinical trials, which can reach up to 90 percent. This article highlights non-animal models that could expedite the drug delivery process from bench to bedside.
-
ArticleNext-generation CAR T cells
Dr John Maher discusses the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours.
-
ArticleDrug Target Review Screening eBook 2023
In this eBook, uncover the transformative potential of AI/ML in single-cell technologies and gain insights into disease progression.
-
ArticleGame-changing pan-TEAD inhibitor for solid tumours
Insilico Medicine has announced the nomination of ISM6331 as a potential best-in-class pan-TEAD inhibitor for the treatment of advanced solid tumours.
-
ArticleChemotherapy-free treatment for patients with blood cancer
Dr Andy Souers highlights the unwavering commitment to finding an enhanced therapeutic approach that eliminates the need for chemotherapy in blood cancer treatment. This transformative discovery represents a significant leap forward in the way we combat this complex disease, offering new hope to countless patients worldwide.
-
NewsNew method of designing drugs without side effects
Japanese researchers now reveal a new way of activating GPCR by triggering shape changes in the intracellular region of the receptor. This new process can help researchers design drugs with fewer or no side effects.
-
ArticleAlgae: a source for prebiotics and drugs to treat IBD
An increasing number of people worldwide suffer from inflammatory bowel disease (IBD). However, no treatment is effective for all patients. In this article, researchers working on the Algae4IBD project explain how algae may represent a valuable source of prebiotics and new therapeutic agents for IBD and other diseases.